The psychedelic medicine industry is transitioning from academic research to viable commercial opportunities. Psilocybin and LSD-based therapies are gaining regulatory approval and investor interest for treating mental health disorders. Major pharmaceutical companies and specialized biotech firms are now developing clinical protocols, securing funding, and advancing through FDA trials. This shift represents a fundamental change in how society perceives and utilizes these compounds for therapeutic purposes, moving beyond decades of prohibition toward evidence-based medical applications.

Summary auto-generated by AI from the original publisher's content. Editorial standards.